ViewRay

ViewRay, Inc. designs, manufactures and markets magnetic resonance imaging (MRI) system. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.

WASHINGTON--(BUSINESS WIRE)--In light of ViewRay Systems recent announcement that it would close its doors on October 25, 2023, Dr. Suthanthiran, President/Founder of TeamBest Global Companies (TBG) and Best Cure Foundation, is encouraging all to share their thoughts as to how to preserve, upgrade, innovate, and reduce the cost of technology, service, etc., of ViewRay Systems products—for now and in the future. Suthanthiran has already received numerous inquiries from customers, vendors, and se.

Open Letter to ViewRay Customers, Service, Software Engineers and Suppliers—Let's Preserve ViewRay Technology

WASHINGTON--(BUSINESS WIRE)--Since the announcement regarding the closing of ViewRay on October 25, 2023, competitors have raced to decommission the ViewRay Systems, replacing them with their own products by establishing relationships with companies that service/decommission/sell refurbished or used equipment—making time of the essence to preserve this valuable technology. While competitors may be motivated to remove ViewRay's systems and offer alternatives, there's a real possibility that the.

Letter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies

WASHINGTON--(BUSINESS WIRE)--Krishnan Suthanthiran offers a solution for continued support and service to ViewRay customers.

Open Letter to ViewRay Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies

DENVER , July 21, 2023 /PRNewswire/ -- ViewRay, Inc. (the "Company") (Nasdaq: VRAY) announced today that on July 17, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"). Nasdaq has determined that due to the Company's voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code, and concerns about the Company's ability to sustain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on Nasdaq based on Listing Rule 5450(a)(1), the Company's securities will be delisted from the Nasdaq Stock Market.

ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets

ViewRay (NASDAQ: VRAY ) stock is falling hard on Monday after the MRI company announced its voluntary Chapter 11 bankruptcy filing! According to the company's bankruptcy filing, ViewRay intends to pursue the sale of its business as part of the Chapter 11 process.

Why Is ViewRay (VRAY) Stock Down 69% Today?

Debtor-in-Possession Financing Secured to Support Ongoing Operations and Chapter 11 Process DENVER , July 17, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that it and certain of its subsidiaries (collectively, "the Company") filed voluntary petitions for relief (the "Petitions") under Chapter 11 of Title 11 the U.S. Bankruptcy Code ("Chapter 11") in the United States Bankruptcy Court for the District of Delaware (the "Court"). The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, including a sale of all or a portion of the Company's assets, while continuing to support its customers during the Chapter 11 process.

ViewRay® Files Voluntary Chapter 11 Petitions

First cancer center in Oklahoma and fourth VA medical center to offer advanced MRI-guided radiation therapy to treat cancer. DENVER , June 13, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the VA Oklahoma City Healthcare System has selected MRIdian MRI-guided radiation therapy system to expand radiation therapy services at the Oklahoma City VA Medical Center.

VA Oklahoma City Healthcare System Chooses ViewRay's MRIdian® MRI-Guided Radiation Therapy System

Coherus BioSciences

Intercept Pharma

Surmodics

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)

ViewRay, Inc. (NASDAQ:VRAY ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Matt Harrison - Director of IR Scott Drake - President and CEO Jake Signoriello - VP of Finance Paul Ziegler - EVP and Chief Commercial Officer Conference Call Participants Rick Wise - Stifel Chris Pasquale - Nephron Suraj Kalia - Oppenheimer Marie Thibault - BTIG Jason Bednar - Piper Sandler Operator Good afternoon, and thank you for joining the ViewRay First Quarter Earnings Call. My name is Kate, and I will be the moderator for today's call.

ViewRay, Inc. (VRAY) Q1 2023 Earnings Call Transcript

50 clinical presentations and posters highlight benefits of MRI-guided radiation adaptive therapy DENVER , May 12, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO) with over 50 presentations and posters highlighting MRIdian clinical and research experience. This year's ESTRO meeting will be held May 12-16, 2023, in Vienna, Austria.

ViewRay's MRIdian® to be Featured at Leading European Radiation Oncology Meeting

ViewRay (VRAY) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.14 per share a year ago.

ViewRay (VRAY) Reports Q1 Loss, Misses Revenue Estimates

DENVER , May 10, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights Total revenue for the first quarter 2023 was approximately $22.5 million, primarily from three revenue units, compared to approximately $18.9 million, primarily from three revenue units, in the first quarter of 2022.

ViewRay Announces First Quarter 2023 Results

DENVER , May 9, 2023 /PRNewswire/ --ViewRay, Inc. (NASDAQ: VRAY) announced today details relating to the release of first quarter 2023 financial results. ViewRay will hold a conference call to discuss results on Wednesday, May 10, 2023 at 4:30 p.m.

ViewRay Announces Conference Call for First Quarter 2023 Financial Results to be Held After Market on May 10, 2023

ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate ViewRay (VRAY) to Report a Decline in Earnings: What to Look Out for

Magnetic resonance imaging-guided radiation therapy system provider ViewRay, Inc. has shocked investors with a severe revenue and cash flow warning. Expected 2023 revenue growth range slashed from a range of 25% to 40% to a new range of 0% to 15%.

ViewRay: Shares Crater As Company Warns Of Slower Growth, Higher Cash Burn

DENVER , April 13, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today provided a business update and announced preliminary financial results for the quarter ended March 31, 2023. The preliminary results have not been audited and are subject to change.

ViewRay Announces Preliminary First Quarter 2023 Results and Updated Fiscal Year 2023 Financial Guidance; Company to Explore Strategic Alternatives to Maximize Shareholder Value

DENVER , April 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) will hold a conference call to discuss results on Thursday, April 13, 2023, at 8:00 AM ET. The dial-in number for domestic callers is (888) 886-7786.

ViewRay Announces Conference Call for Preliminary First Quarter 2023 Financial Results to be held Pre-Market opening on April 13, 2023

BlackBerry

BigBear.ai Holdings

Kinross Gold

OPKO Health

Sirius XM Holdings Inc

SoundHound AI Inc

Penny stocks with unusual options activity. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 7 With Unusual Options Volume This Week

FORT MYERS, Fla.--(BUSINESS WIRE)--GenesisCare, one of the leading integrated cancer care providers in the United States, Australia, Spain, and the United Kingdom, will launch ViewRay's advanced MRIdian MRI-guided radiation therapy system at the Lee Health Regional Cancer Center on Monday, March 27, at its Fort Myers, FL location.

GenesisCare Launches ViewRay MRIdian® MRI-Guided Radiation Therapy System at Lee Health Regional Cancer Center, Empowering Cancer Patient Care with an Innovative Radiotherapy Approach with Reduced Side Effects, Fewer Sessions Needed

First and only MRIdian in the Czech Republic to bring advanced MRI-guided radiation therapy to the region DENVER , March 7, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced the Czech Ministry of Health has approved the purchase of ViewRay's MRIdian system to bring advanced MRI-guided radiation therapy to treat its cancer patients at the Military University Hospital Prague in the Czech Republic. This is the first and only hospital to offer the precision of MRIdian Stereotactic MRI-guided Adaptive Radiotherapy (SMART) in the Czech Republic.

Military University Hospital Prague Selects ViewRay's MRIdian® MRI-Guided Radiation Therapy System to Treat Cancer Patients

World's first MRIdian center at Barnes-Jewish Hospital continues to lead the way for advanced precision cancer therapy with MRI-guided radiation DENVER , March 2, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the clinical team at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis has treated its 2,000th patient using the MRIdian, MRI-guided radiation therapy system. Patients treated at Siteman Cancer Center benefit from MRIdian's diagnostic quality MR visualization on-table adaptive radiotherapy, real-time tissue tracking, and automated beam control.

Siteman Cancer Center at Washington University Treats 2,000th Patient with MRIdian® MRI-Guided Radiation Therapy

ViewRay, Inc. (NASDAQ:VRAY ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Matt Harrison - Director of IR Scott Drake - President and CEO Bill Burke - CFO Conference Call Participants Rick Wise - Stifel Jason Bednar - Piper Sandler Chris Pasquale - Nephron Research Suraj Kalia - Oppenheimer Operator Good afternoon, ladies and gentlemen. And welcome to the ViewRay Q4 2022 Earnings Call.

ViewRay, Inc. (VRAY) Q4 2022 Earnings Call Transcript

ViewRay (VRAY) delivered earnings and revenue surprises of 6.25% and 0.71%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ViewRay (VRAY) Reports Q4 Loss, Misses Revenue Estimates

DENVER , Feb. 27, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the fourth quarter and full fiscal year ended December 31, 2022. Full Year 2022 Highlights Total revenue of $102.2 million primarily from 16 revenue units including one upgrade, compared to 2021 revenue of approximately $70.1 million, primarily from ten revenue units.

News for ViewRay Stock (VRAY)